Ryan & Maniskas, LLP Announces Investigation of Human Genome Sciences Inc.
17 Juillet 2012 - 9:05PM
Business Wire
Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/hgsi) is
investigating potential claims against the board of directors of
Human Genome Sciences Inc. (“Human Genome” or the “Company”)
(NASDAQ: HGSI) concerning possible breaches of fiduciary duty and
other violations of law related to the Company’s efforts to sell
Human Genome to GlaxoSmithKline plc in a transaction valued at
approximately $3 billion.
Our investigation concerns possible breaches of fiduciary duty
and other violations of law related to the approval of the
transaction by the Company’s board of directors; in particular,
whether the Company undertook a fair process to obtain fair
consideration for all shareholders of Human Genome. For more
information regarding our investigation, please contact Ryan &
Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877)
316-3218 or by email at rmaniskas@rmclasslaw.com or visit:
www.rmclasslaw.com/cases/hgsi.
Under the terms of the transaction, Human Genome shareholders
will receive $14.25 per share of Human Genome stock they own.
If you own shares of Human Genome and would like to learn more
about these claims or if you wish to discuss these matters and have
any questions concerning this announcement or your rights, contact
Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign
up online, visit: www.rmclasslaw.com/cases/hgsi. You may also email
Mr. Maniskas at rmaniskas@rmclasslaw.com. For more information
about class action cases in general, please visit our website:
www.rmclasslaw.com.
Ryan & Maniskas, LLP is a national shareholder litigation
firm. Ryan & Maniskas, LLP is devoted to protecting the
interests of individual and institutional investors in shareholder
actions in state and federal courts nationwide.
Human Genome Sciences (NASDAQ:HGSI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Human Genome Sciences (NASDAQ:HGSI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Human Genome Sciences, Inc. (MM) (NASDAQ): 0 recent articles
Plus d'articles sur Ryan & Maniskas, LLP